الفهرس 
Systemic Lupus ErythematosusOnly 14 pages are availabe for public view
 |  | from | 161 |  |  |
| | | from | 161 | | |
Abstract
ABSTRACT
Background: Inflammatory bowel diseases (IBD) consist of Crohn’s disease (CD) and ulcerative colitis (UC). They are characterized by a chronic relapsing and remitting disease course that results in intestinal symptoms but also frequently in extra-intestinal manifestations. Among potential targets and biomarkers, oncostatin M (OSM) has gained a lot of interest. OSM is a pleiotropic cytokine produced by activated T cells, monocytes, macrophages, and neutrophils. It is considered proinflammatory given its ability to promote leukocyte recruitment.
Objective: To evaluate the changes in serum Oncostatin M levels during treatment of inflammatory bowel disease.
Patients and Methods: To elucidate this aim 30 IBD patients and 30 controls were included in this study.
Results: The mean Oncostatin M in IBD cases before treatment was 120.13 while after treatment was 91.17 with high significant difference. There was high statistical correlation in between Fecal Calprotectin Level after treatment and Oncostatin M After Treatment. The relation between UC, CD and Oncostatin level before and after treatment shows high statistical significant difference. There was no statistical relation in between Oncostatin level (after treatemnt) and type of treatment. That there was a high statistically significant difference in between cases and control group regarding to HB, WBCs, ESR, CRP, Urea, ALT, Oncostatin M and a statistically significant difference in between cases and control group regarding to Platelets.
Conclusion: Oncostatin M is a promising marker for the diagnosis and follow up of IBD patients, however it has a limited predictive performance for the prediction of the response for IBD treatment.